KMT2A and myeloid sarcoma: Coincidently, patients with de novo MS harbor genetic abnormalities like RUNX1-RUNX1T1, CBFB-MYH11, KMT2A-MLLT3, and JAK2 V617F, whereas KMT2A and BCR-ABL1 rearrangements have been observed in secondary cases [31].